The estimated Net Worth of Venture Partners V Lp Skyli... is at least $13.6 Million dollars as of 12 May 2015. Venture Skyli owns over 150,000 units of Sutro Biopharma Inc stock worth over $13,599,113 and over the last 10 years Venture sold STRO stock worth over $0.
Venture has made over 1 trades of the Sutro Biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Venture bought 150,000 units of STRO stock worth $1,800,000 on 12 May 2015.
The largest trade Venture's ever made was buying 150,000 units of Sutro Biopharma Inc stock on 12 May 2015 worth over $1,800,000. On average, Venture trades about 75,000 units every 0 days since 2015. As of 12 May 2015 Venture still owns at least 2,949,916 units of Sutro Biopharma Inc stock.
You can see the complete history of Venture Skyli stock trades at the bottom of the page.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund und Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: